Stock market today: Stocks stall but cap winning week as Trump's remarks rattle Wall Street
Published On Jan 24, 2025, 4:04 PM
U.S. stocks experienced a decline on Friday as investors processed recent earnings reports and President Trump’s easing of tariff threats against China. Although the Dow Jones and S&P 500 both slipped 0.3%, they finished the week with a 3% gain. Investor sentiment was positively impacted throughout the week by Trump's comments including his desire for cuts in U.S. interest rates and taxes. Key technology companies are set to report earnings next week, adding to market anticipation. Notable stock movements included Novo Nordisk, whose shares rose over 7% on promising results for a new weight-loss drug, and Boeing, which fell 1% after announcing a significant quarterly loss.
Stock Forecasts
NVO
Positive
Trump's softened tariff stance may stabilize investor confidence and support a continued rally, especially in sectors sensitive to trade policy. Expect tech stocks to remain in focus, particularly with upcoming earnings reports from major companies. Amid the positive sentiment, Novo Nordisk's strong performance is indicative of potential growth in the healthcare sector.
BA
Negative
Despite recent gains, Boeing's forecasted loss could negatively impact investor sentiment, particularly if their next earnings report fails to reassure the market about recovery plans and profitability.
MSFT
Neutral
Tech stocks are poised for volatility as major earnings loom. Companies like Microsoft, Meta, and Apple could see trading fluctuations based on earnings results, impacting overall market sentiment and possibly creating investment opportunities depending on performance.
Related News
Stock market today: Dow, S&P 500, Nasdaq stall as investors weigh earnings, Trump on China
Jan 24, 2025, 3:36 PM
Wall Street stocks are on track for weekly wins as markets ride the Trump roller-coaster.
Stock market today: Dow, S&P 500, Nasdaq stall as investors weigh earnings, Trump on China
Jan 24, 2025, 1:15 PM
Wall Street stocks are on track for weekly wins as markets ride the Trump roller-coaster.
Novo Nordisk stock pops on phase I data for new weight-loss drug amycretin
Jan 24, 2025, 9:47 AM
Novo Nordisk announces new early clinical trial data for its latest weight loss drug, amecrytin.